Riboxin-BHFZ film-coated tablets 200 mg blister No. 50

Pharmacological properties

A metabolic type of action agent used to treat heart diseases. Inosine has antihypoxic, antiarrhythmic properties and exhibits anabolic effects, being a precursor of ATP. It has a positive effect on metabolism in the myocardium, in particular, it increases the activity of a number of enzymes that ensure cell respiration. It increases the force of heart contractions and promotes more complete relaxation of the myocardium in diastole due to the ability to bind calcium ions that penetrate the cells during their excitation. As a result, the stroke volume of the heart increases, and the blood supply to tissues, including the myocardium, improves. Inosine also reduces platelet aggregation and stimulates tissue regeneration (especially the myocardium and the mucous membrane of the digestive tract).

Indication

Inosine-BHFZ is used in the complex treatment of coronary heart disease (myocardial infarction, angina pectoris, heart rhythm disturbances); in poisoning with digitalis drugs, for the treatment of cardiomyopathies of various genesis, myocarditis, myocardial dystrophy (against physical overload, in infectious and endocrine diseases), liver diseases (hepatitis, cirrhosis, fatty dystrophy), gastric and duodenal ulcers, uroporphyria, for the prevention of leukopenia during irradiation. As a means of improving visual function, it is used in open-angle glaucoma with normalized (with the help of antihypertensive drugs) intraocular pressure.

Application

Inside before meals. The daily dose is set individually and is 0.6-2.4 g per day. Usually, at the beginning of treatment, the drug is prescribed in a daily dose of 0.6-0.8 g (1 tablet 3-4 times a day). With good tolerability of the drug, the dose is gradually (within 2-3 days) increased first to 1.2 g per day (2 tablets 3 times a day), then to 2.4 g per day (4 tablets 3 times a day). The duration of treatment is from 4 weeks to 1.5-3 months. In uroporphyria, inosine-BHFZ is prescribed at 0.8 g per day (1 tablet 4 times a day). The duration of the course of treatment is 1-3 months.

Contraindication

Increased individual sensitivity to the components of the drug, gout.

Side effects

Patients with hypersensitivity to the drug may experience itching, redness of the skin. Occasionally - tachycardia, increased blood urea levels, with prolonged treatment - exacerbation of gout.

Special instructions

In renal failure, the use of the drug is possible only if the expected positive effect outweighs the possible risk of its use. There is no information on the negative effects of inosine-BCHFZ on drivers and other people working with potentially dangerous equipment.

Interactions

Interactions with other drugs that could lead to a decrease in the effectiveness and safety of the drug have not been established to date.

When taking INOSIN-BHFZ simultaneously with β-adrenergic blockers, the effect of the drug does not decrease. When used together with cardiac glycosides, the drug can prevent the occurrence of arrhythmias.

Overdose

The described side effects may be intensified.

Storage conditions

In a dry place, protected from light, at a temperature not exceeding 25 ° C. Shelf life - 3 years.